DavidMichaelPiontkowskyMD

PubMed

• 15 citations
  Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed peo...
  Franco Maggiolo, Giuliano Rizzardini, Jean-Michel Molina, Federico Pulido, Stephane De Wit
  HIV Medicine. 2023-01-01
• 5 citations
  Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation
  Ignacio Pérez-Valero, Josep M. Llibre, Antonella Castagna, Federico Pulido, Jean-Michel Molina
  Journal of Acquired Immune Deficiency Syndromes. 2021-04-01
• 29 citations
  Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial.
  Franco Maggiolo, Giuliano Rizzardini, Jean-Michel Molina, Federico Pulido, Stéphane De Wit
  Infectious Diseases and Therapy. 2021-03-09

Journal Articles

• SWIFT: Prospective 48 Week Study to Evaluate Efficacy and Safety of Switching to Emtricitibine/Tenofovir from Lamivudine/Abacavir in Virologically Suppressed HIV-1 Inf...  
  Campo, R, DeJesus, E, Bredeek, UF, Henry, K, Khanlou, H, Logue, K, Brinson, C, Benson, P, Wang, HJ, White, K, Dau, L, Flaherty, J, Fralich, T, Guyer, B, Piontkowksy, D, Clinical Infectious Disesases, 6/2013

Abstracts/Posters

• Budget impact of the introduction of elvitegravir/cobicistat/emtricitabine/tenofovir, the first integrase inhibitor-based single tablet antiretroviral regimen for HIV ...
  Brogan, A, Talbird, SE, Thompson, JR, Kim, YA, Olson, J, Peterson, J, Piontkowsky, D, Pietrandoni, G, ISPOR, Dublin, Ireland, 11/2013
• Week 96 Renal Safety Update of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF from two phase 3 randomized controlled trials
  Post, F, Winston, J, Hendry, B, Gazzard, Piontkowsky, D, Cheng, A, Rhee, M, Szwarcberg, J, Journal of International AIDS Society, 7/2013
• Elvitegravir/cobicistat/emtricitabine/tenofovir DF, demonstrates comparable efficacy to efavirenz/emtricitabine/tenofovir DF in subjects with adherence <95%
  Shalit, P, Cohen, C, Mills, A, Bredeek, F, Crofoot, G, Nguyen, T, Dau, T, Rhee, M, Piontkowsky, D, Szwarcberg, J, International AIDS Conference, Washington DC, 7/2013
• Analysis of EVG/COBI/FTC/TDF Compared to EFV/FTC/TDF by Race in Treatment Naive Patients
  Hardy, D, Ruane, P, Workowski, K, Rhee, M, Piontkowsky, D, IDSA, San Diego, 10/2012
• SWIFT: Switching from Lamivudine/Abacavir to Emtricitabine/Tenofovir Improved Lipids While Maintaing Virologic Suppression in Oler HIV Subjects
  Henry, K, DeJesus, E, Campo, R, Bredeek, UF, Wang, H, Dau, L, Piontkowsky, D, Bosse, M, 10th Annual Conference of the British HIV Association, 2012
• Cidofovir-induced renal failure for treatment of AIDS-associated progressive multifocal leukoencephalopathy
  Wochinger, K, Chan-Tompkins, N, and Piontkowsky, D, American Society of Health System Pharmacists, 12/2006
• Creatinine elevation trends in patients prescribed emtricitabine/tenofovir or tenofovir
  Piontkowsky, D, Doran, B, Heintz, J, Chan-Tompkins, NH, International AIDS Conference, 2006
• Hepatitis C and HIV Co-Infection in an Urban Infectious Disease Clinic
  Piontkowsky, D, and Crane, L, Michigan Infectious Disease Society, 3/27/2003
• Smoking Cessation in an Urban Internal Medicine Clinic
  Piontkowsky, D, American College of Physicians--American Society of Internal Medicine, Michigan Chapter, 9/12/2002
• Staphylococcus Aureus Endocarditis Presenting as Scrotal Swelling
  Piontkowsky, D, American College of Physicians--American Society of Internal Medicine, Michigan Chapter, 9/12/2002
• Join now to see all